Company Overview of Aphton Corp.
Aphton Corp., a clinical stage biopharmaceutical company, engages in the research and development of cancer immunotherapies. It offers products based on its proprietary active immunization, as well as monoclonal antibody technologies. The company’s products include IGN101, a Phase II/III randomized double-blind clinical trial in non small cell lung cancer patients, is a cancer vaccine designed to induce an immune response against epithelial cell adhesion molecule positive tumor cells; IGN311, which completed an open-label dose escalating Phase I trial, is a monoclonal antibody targeting Lewis Y-positive cancer cells; and Insegia, which is under various clinical trials for gastrointestinal ca...
8 Penn Center
1628 JFK Boulevard Suite 2300
Philadelphia, PA 19103
Founded in 1981
Key Executives for Aphton Corp.
Co-Founder, Chairman Emeritus and Chairman of Executive Committee
Chief Financial Officer, Chief Accounting Officer and Executive Vice President
Chief Scientific Officer and Executive Vice President
Vice President and Medical Director for Clinical Trials & Regulatory Affairs - Europe & Asia
Chief Scientific Officer of Igeneon
Compensation as of Fiscal Year 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries